Cord Blood News Volume 4.22 | Jun 7 2012

The Novel Tribody [(CD20)₂ × CD16] Efficiently Triggers Effector Cell-Mediated Lysis of Malignant B Cells
In mice with a reconstituted humanized hematopoietic system established by transplantation of human CD34-positive cord blood cells the novel tribody [(CD20)₂ × CD16] significantly depleted autologous human B cells. [Leukemia] Abstract

Amniotic Fluid Stem Cells Restore the Muscle Cell Niche in a HSA–Cre, Smn^F7/F7 Mouse Model
Mice carrying a homozygous deletion of the survival of motor neuron gene (Smn) exon 7 directed to skeletal muscle (HSA–Cre, Smn^F7/F7 mice) present clinical features of human muscular dystrophies for which new therapeutic approaches are highly warranted. In this study, researchers demonstrated that tail vein transplantation of mouse amniotic fluid stem cells enhances the muscle strength and improves the survival rate of the affected animals. [Stem Cells] Abstract | Press Release

Cobalt Chloride Enhances Angiogenic Potential of CD133⁺ Cells
Investigators determined whether CD133⁺ cells enhance angiogenic potential through hypoxia or hypoxia mimetic agent (CoCl₂) in vitro. [Front Biosci] Abstract

Toxicity of Clopidogrel and Ticlopidine on Human Myeloid Progenitor Cells: Importance of Metabolites
Aims of this study were to find out whether non-metabolized drug and/or metabolites are responsible for myelotoxicity and whether the inactive clopidogrel metabolite clopidogrel carboxylate contributes to myelotoxicity. Researchers used myeloid progenitor cells isolated from human umbilical cord blood in a colony-forming unit assay to assess cytotoxicity. [Toxicology] Abstract

Ex Vivo Expansion of Cord Blood-CD34+ Cells Using IGFBP2 and Angptl-5 Impairs Short-Term Lymphoid Repopulation In Vivo
The yield of cord blood (CB)-derived hematopoietic stem cells per graft is limited and often insufficient, particularly for the treatment of adult patients. Here researchers compared the capacity of three cytokine cocktails to expand CB-CD34⁺ cells. [J Tissue Eng Regen Med] Abstract

Combination of Temperature Sensitive Stem Cell and Mild Hypothermia: A New Potential Therapy for Severe Traumatic Brain Injury
The authors observed that combinational therapy of hypothermia and temperature sensitive mesenchymal stem cells from umbilical cord exerted the most protective effect on recovery of neurological function among all treatments with highest survival rate, proliferation and lowest apoptosis, which may provide a new therapeutic strategy for severe traumatic brain injury. [J Neurotrauma] Abstract

Human Umbilical Cord Blood-Derived Mesenchymal Stem Cell Transplantation Attenuates Severe Brain Injury by Permanent Middle Cerebral Artery Occlusion in Newborn Rats
Researchers hypothesized that human umbilical cord blood-derived mesenchymal stem cells can attenuate severe brain injury induced by permanent middle cerebral artery occlusion in rat pups. [Pediatr Res] Abstract

Systemic Delivery of Human Mesenchymal Stromal Cells Combined with IGF-1 Enhances Muscle Functional Recovery in LAMA2^dy/2j Dystrophic Mice
Scientists demonstrated that IGF-1 considerably enhances the myogenesis of human umbilical cord mesenchymal stromal cells (MSCs) in vitro and that IGF-1 enhances interaction and restoration of dystrophin expression in co-cultures of MSCs and muscle cells from Duchenne patients. [Stem Cell Rev] Abstract

AuxoCell Laboratories Licenses Umbilical Cord Tissue Stem Cell Service to Brazil’s CordVida
AuxoCell Laboratories, Inc. announced an agreement with CordVida which will allow CordVida to expand its services. Families who select CordVida to store umbilical cord blood will now have the opportunity to bank stem cells from an additional source – cord tissue. With this agreement, AuxoCell broadens its international reach to South America. [Business Wire] Press Release

Marken Launches Cord Blood Service in the US and Latin America
Marken announced that it has successfully rolled out a new comprehensive service to collect and deliver cord blood from US and Latin American hospitals to storage facilities in the United States. [PR Newswire]
Press Release

Northside Hospital Blood and Marrow Transplant Program Remains #1 Nationally in Best Survival Outcomes
The National Marrow Donor Program has released data that indicate Northside Hospital’s Blood & Marrow Transplant Program has, by far, the best survival rates for matched related and unrelated transplants of any program in the country. This is the third consecutive year that Northside has come out on top. [Northside Hospital, Inc.] Press Release

National Institutes of Health (United States)

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)

NEW World Cord Blood Congress
September 20-21, 2012
Boston, United States

NEW Epigenetics and Stem Cells 2012
October 16-17, 2012
Cambridge, United Kingdom

Visit our events page to see a complete list of events in the cord blood community.

Scientist – hPSC Bioengineering (STEMCELL Technologies, Inc.)

Scientist – Epithelial Cell Research (STEMCELL Technologies, Inc.)

Scientist – Induced Pluripotent Stem Cells (STEMCELL Technologies, Inc.)

Scientist – Mesenchymal Cell Research (STEMCELL Technologies, Inc.)

Research Associate – Chemistry (STEMCELL Technologies, Inc.)

Research Associate – Particle Chemistry (STEMCELL Technologies, Inc.)

Research Technologist – Contract Assay Services (STEMCELL Technologies, Inc.)

Research Technologist – Media Development (STEMCELL Technologies, Inc.)

Business Analyst – Product Management (STEMSOFT Software, Inc.)

Business Development Manager – Stem Cell (SynGen Inc.)

Controller (SynGen Inc.)

Director: Regulatory Affairs (SynGen Inc.)

Manufacturing Manager (SynGen Inc.)

Chief Scientific Officer (SynGen Inc.)

Development Scientist – Cell Therapy (GE Healthcare)

Group Leaders, Principle Scientists – Stem Cell Clinical Product R&D (Shanghai Hengrui Pharmaceuticals Co., Ltd)

Histocompatibility & Immunogenetics Service Development Scientist (NHS Blood and Transplant)


Recruit Top Talent: Reach more than 50,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.

Have we missed an important article or publication in Cord Blood News? Click here to submit!

Comments or Suggestions? Email info@connexoncreative.com with your feedback.